{"id":"NCT04209205","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-29","primaryCompletion":"2022-05-17","completion":"2022-05-17","firstPosted":"2019-12-24","resultsPosted":"2024-04-26","lastUpdate":"2025-05-16"},"enrollment":381,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"AIN457 6 mg/kg i.v.","otherNames":["secukinumab"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"AIN457 3 mg/kg","otherNames":["secukinumab"]}],"arms":[{"label":"AIN457 6 mg/kg - 3 mg/kg i.v.","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA) despite current or previous Non-steroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARDs) and/or anti-tumor necrosis factor (TNF) therapy.","primaryOutcome":{"measure":"Percentage of Participants With American College of Rheumatology 50 (ACR50) Response Comparison Between Treatment Groups Using Non-responder Imputation at Week 16 (Full Analysis Set)","timeFrame":"Baseline up to Week 16","effectByArm":[{"arm":"AIN457 6 mg/kg - 3 mg/kg i.v.","deltaMin":31.35,"sd":null},{"arm":"Placebo to AIN457 3 mg/kg i.v.","deltaMin":6.33,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":80,"countries":["United States","Brazil","Bulgaria","Colombia","Czechia","Greece","Guatemala","India","Malaysia","Philippines","Poland","Russia","South Africa","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1500"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":374},"commonTop":["COVID-19","Urinary tract infection","Arthralgia","Headache","Nasopharyngitis"]}}